Can repairing damage from menopause greatly extend life?

Menopause-associated skeletal remodeling generates an unexpected systemic anticancer restraint: osteoclast-derived matrix metalloproteinase-9 releases circulating tumstatin from collagen IV, suppressing vascularization of occult tumors. In a susceptible subgroup, correcting excessive remodeling removes enough of this restraint to increase cancer mortality despite preventing fractures. The competing failures are therefore biologically coupled through proteolysis, rather than merely competing statistically. Preserving the antiangiogenic fragment while correcting skeletal injury would stabilize SPV_11; skeletal correction alone would encounter a survival ceiling.

Restoring tumstatin to its pretreatment concentration abolishes the cancer acceleration while retaining skeletal benefit, with lead exposure and IgG glycosylation held comparable. Failure to demonstrate an osteoclast-dependent contribution to circulating tumstatin rejects this mechanism before survival testing.

In a factorial comparison, adding a post-injury cascade-interruption program makes some of the survival benefit of fracture prevention redundant because both prevent the same downstream events. The mechanism fails if preventing initiating injuries leaves the prespecified downstream event burden unchanged with sufficiently narrow uncertainty.

Menopausal bone remodeling may release stored lead and injure multiple organs predicts instead: With comparable skeletal improvement, reductions in circulating lead and subsequent renal or vascular deterioration are substantially larger in participants with high pretreatment bone lead. In preclinical models, restoring circulating lead to the untreated concentration abolishes these extra-skeletal benefits without abolishing bone preservation. Persistence of equal extra-skeletal benefit in negligible-lead models, or after matched lead replacement, rejects this explanation.

Estrogen withdrawal may alter antibody sugars and amplify injury across organs predicts instead: In paired experiments using the same purified IgG preparation, enzymatic correction of Fc glycans reduces complement deposition and injury in multiple tissue assays while preserving antibody concentration and antigen specificity. Sham-edited IgG retains the injury phenotype. In an appropriate aged-animal model, glycan correction reduces multisystem injury without changing skeletal turnover, lead exposure or tumstatin. Failure of glycan editing to alter effector activity rejects this mechanism even if hormone treatment changes a glycan-age score.

Menopause-associated injuries seed self-exciting sequences of otherwise distinct illnesses. A fracture initiates immobility and hospitalization, increasing infection and cardiovascular-event probabilities; those events further increase subsequent disability and illness. Correcting an initiating injury can therefore reduce several causes of death without changing a common molecular aging process. Stabilizing SPV_11 depends on extinguishing these event cascades, whereas correcting a pathway that rarely initiates cascades produces only isolated disease prevention.

In a factorial comparison, adding a post-injury cascade-interruption program makes some of the survival benefit of fracture prevention redundant because both prevent the same downstream events. The mechanism fails if preventing initiating injuries leaves the prespecified downstream event burden unchanged with sufficiently narrow uncertainty.

Restoring tumstatin to its pretreatment concentration abolishes the cancer acceleration while retaining skeletal benefit, with lead exposure and IgG glycosylation held comparable. Failure to demonstrate an osteoclast-dependent contribution to circulating tumstatin rejects this mechanism before survival testing.

Menopausal bone remodeling may release stored lead and injure multiple organs predicts instead: With comparable skeletal improvement, reductions in circulating lead and subsequent renal or vascular deterioration are substantially larger in participants with high pretreatment bone lead. In preclinical models, restoring circulating lead to the untreated concentration abolishes these extra-skeletal benefits without abolishing bone preservation. Persistence of equal extra-skeletal benefit in negligible-lead models, or after matched lead replacement, rejects this explanation.

Estrogen withdrawal may alter antibody sugars and amplify injury across organs predicts instead: In paired experiments using the same purified IgG preparation, enzymatic correction of Fc glycans reduces complement deposition and injury in multiple tissue assays while preserving antibody concentration and antigen specificity. Sham-edited IgG retains the injury phenotype. In an appropriate aged-animal model, glycan correction reduces multisystem injury without changing skeletal turnover, lead exposure or tumstatin. Failure of glycan editing to alter effector activity rejects this mechanism even if hormone treatment changes a glycan-age score.

In people with substantial historical lead exposure, accelerated menopausal bone remodeling reintroduces skeletal lead into circulation. The resulting toxicant exposure contributes to renal, vascular and neurological injury simultaneously. Correcting skeletal remodeling could therefore stabilize SPV_11 through reduced multisystem poisoning as well as fracture prevention. The shared-cause benefit should be strongly concentrated in participants with high skeletal lead burden; low-burden participants would retain mainly the narrower skeletal benefit.

In preclinical models, restoring circulating lead to the untreated concentration abolishes these extra-skeletal benefits without abolishing bone preservation. Persistence of equal extra-skeletal benefit in negligible-lead models, or after matched lead replacement, rejects this explanation.

Restoring tumstatin to its pretreatment concentration abolishes the cancer acceleration while retaining skeletal benefit, with lead exposure and IgG glycosylation held comparable. Failure to demonstrate an osteoclast-dependent contribution to circulating tumstatin rejects this mechanism before survival testing.

Menopause-associated injuries may trigger cascades of illness that increase mortality predicts instead: Randomized fracture prevention reduces subsequent pneumonia and cardiovascular events in the time windows predicted from independently estimated event-triggering kernels, despite unchanged lead, tumstatin and IgG-glycan profiles. In a factorial comparison, adding a post-injury cascade-interruption program makes some of the survival benefit of fracture prevention redundant because both prevent the same downstream events. The mechanism fails if preventing initiating injuries leaves the prespecified downstream event burden unchanged with sufficiently narrow uncertainty.

Estrogen withdrawal may alter antibody sugars and amplify injury across organs predicts instead: In paired experiments using the same purified IgG preparation, enzymatic correction of Fc glycans reduces complement deposition and injury in multiple tissue assays while preserving antibody concentration and antigen specificity. Sham-edited IgG retains the injury phenotype. In an appropriate aged-animal model, glycan correction reduces multisystem injury without changing skeletal turnover, lead exposure or tumstatin. Failure of glycan editing to alter effector activity rejects this mechanism even if hormone treatment changes a glycan-age score.

Estrogen withdrawal changes IgG Fc glycosylation, altering how existing antibodies engage complement and Fc receptors. A pathogenic glycan distribution thereby amplifies injury across several organs without requiring new antibody specificities. Correcting this effector chemistry could stabilize SPV_11 by reducing a shared immune-injury mechanism, whereas correcting bone or vascular lesions while leaving antibody effector activity unchanged would preserve continuing cross-organ injury.

Sham-edited IgG retains the injury phenotype. In an appropriate aged-animal model, glycan correction reduces multisystem injury without changing skeletal turnover, lead exposure or tumstatin. Failure of glycan editing to alter effector activity rejects this mechanism even if hormone treatment changes a glycan-age score.

Restoring tumstatin to its pretreatment concentration abolishes the cancer acceleration while retaining skeletal benefit, with lead exposure and IgG glycosylation held comparable. Failure to demonstrate an osteoclast-dependent contribution to circulating tumstatin rejects this mechanism before survival testing.

Menopause-associated injuries may trigger cascades of illness that increase mortality predicts instead: Randomized fracture prevention reduces subsequent pneumonia and cardiovascular events in the time windows predicted from independently estimated event-triggering kernels, despite unchanged lead, tumstatin and IgG-glycan profiles. In a factorial comparison, adding a post-injury cascade-interruption program makes some of the survival benefit of fracture prevention redundant because both prevent the same downstream events. The mechanism fails if preventing initiating injuries leaves the prespecified downstream event burden unchanged with sufficiently narrow uncertainty.

Menopausal bone remodeling may release stored lead and injure multiple organs predicts instead: With comparable skeletal improvement, reductions in circulating lead and subsequent renal or vascular deterioration are substantially larger in participants with high pretreatment bone lead. In preclinical models, restoring circulating lead to the untreated concentration abolishes these extra-skeletal benefits without abolishing bone preservation. Persistence of equal extra-skeletal benefit in negligible-lead models, or after matched lead replacement, rejects this explanation.